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Background: Chemotherapy as an important tool for cancer treatment faces many obstacles 
such as multidrug resistance and adverse toxic effects on healthy tissues. Drug delivery sys-
tems has opened a new window to overcome these problems. There has been a strong interest 
development of new platform and system for delivof chemotherapeutic agents. 
Purpose: In the present study, a green synthesis method was chosen and performed for prepara-
tion of a novel amphoteric calix[4]arene (Calix) macrocycle with low toxicity to the human body. 
Materials and methods: The amphoteric Calix was coated on the surface of Fe
3
O
4
 magnetic 
nanoparticles and used as a magnetic nanocarrier for simultaneous delivery of two anticancer 
agents, doxorubicin and methotrexate, against MCF7 cancer cells. Several chemical charac-
terizations were done for validation of prepared nanocarrier, and in vitro loading and release 
studies of drugs were performed with good encapsulation efficiency. 
Results: In vitro biological studies including hemolysis assay, erythrocytes sedimentation 
rate, red blood cells aggregation, cyto cellular internalization, and apoptosis evaluations were 
performed. Based on results, the developed nanocarrier has many advantages and capability for 
an efficient codelivery of DOX and MTX, which has a highly potent ability to kill cancer cells. 
Conclusion: All these results persuade us, this nanocarrier could be effectively used for cancer therapy 
of MCF7 breast cancer cells and is suitable for use in further animal studies in future investigations.
Keywords: green synthesis, amphoteric calix[4]arene, drug delivery, combination therapy, MCF7 cells
Introduction
Macrocycle molecules are the significant class of drug-delivery vehicle like other 
classes of the delivery vehicle such as carbon nanotubes, nanoparticles, micelles, and 
dendrimers.1–4 There are a large number of macrocycles that are potentially useful 
for drug delivery; only five types have been studied extensively such as calixarenes, 
cyclodextrins, cucurbiturils, cryptands, crown ethers, and their derivatives.5–11 Construc-
tion of drug carrier from these macrocycles is of fundamental interest for applications 
in biotechnology and medicine. Calixarenes are a class of organic macrocyclic host 
molecules and have been widely studied and used in various fields since their discovery 
by David Gutsche around 1970 by the condensation of substituted phenols and formal-
dehyde in the presence of inorganic bases and more rarely acids as the catalyst.12 Since 
calixarenes can be modified by different functionalization at the lower and/or upper 
rims of the molecule, the calixarene derivatives provide useful platforms for anchoring 
a variety of binding units for ions and neutral molecules, and incorporating functional 
groups, such as ester, ether, ketone, amide, and carboxylic acid groups, exhibit excellent 
binding abilities.13–16 Their structures have unique three-dimensional surface, which 
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made them as one of the best-known host molecules and used 
in the biomedical applications of supramolecular systems 
based on host–guest interactions.17,18 A particular interest was 
generated by the possibility of using calixarenes as vehicles 
in drug delivery and other pharmacological contexts.
Nano-sized magnetic particles (Fe
3
O
4
) are recently devel-
oped and their superparamagnetic properties have opened 
promising new perspectives for their application in several 
fields such as drug-delivery systems, MRI, bioseparation, 
etc.19,20 For drug targeting, they can accumulate in desired 
locations within the body by using a permanent external 
magnet.21 Besides, using magnetic particles can significantly 
improve hyperthermia cancer treatment. This kind of therapy 
could raise the temperature of the target tissue to 43°C–46°C, 
which makes cell more sensitive to chemotherapy and may 
show better results. Therefore, applying magnetic nanopar-
ticles as nano-object in drug-delivery systems give several 
advantages to final drug carriers.
Developing drug carrier with either multidrug loading or 
conjugating for codelivery of the chemotherapeutic agents 
is a necessary approach to overcome the multiple drug 
resistance.22–24 The results and evidence revealed that anti-
cancer drugs effects, cytotoxicity, antiproliferative activity, 
tumor cell apoptosis, and the low dose of anticancer drugs 
were increased by using drug carrier with combinational for-
mulations.25 Improving the therapeutic index and overcoming 
the undesirable side effects of anticancer drugs with similar 
and different mechanisms of action is a promising strategy 
to reduce unwanted toxicity.26,27
In recent years, there has been considerable interest in using 
amphiphilic materials as the drug- and gene-delivery system 
for cancer therapy.28–31 The aim of present study is to prepare 
an amphoteric calix[4]arene (Calix) with cationic and anionic 
rim sides by a green approach. Also, the capability of this 
amphoteric carrier was evaluated for MCF7 cells as the human 
breast adenocarcinoma cell line with targeted delivery of DOX 
and MTX as the model anticancer drugs. The novel amphoteric 
nanocarrier showed negligible cytotoxicity and hemolytic 
effects on human red blood cells (RBCs) with good in vitro 
loading efficacy. Finally, to show the capability of drug-loaded 
nanocarrier in killing MCF cancer cells, MTT assay, cellular 
uptake, and Annexin V-FITC, and PI methods were used to 
investigate the apoptotic effect in comparison to free drugs.
Materials and methods
Materials
Some starting materials such as Calix and 1-methyl-
3-(oxirane-2-ylmethyl)–1H-imidazole-3-ium chloride 
(IL-oxirane) were synthesized according to the recent lit-
erature reports.3,6 Ferric chloride hexahydrate (FeCl
3
.6H
2
O), 
ferrous chloride tetrahydrate (FeCl
2
⋅4H
2
O), ammonia solu-
tion (30%), 1-methylimidazole, epichlorohydrin, different 
reagents, and solvents of analytical grade were purchased 
from Merck Co. and used as received. Anticancer drugs were 
obtained from Zahravi Pharmaceutical Co. (Tabriz, Iran) and 
Sobhan Pharmaceuticals Co. (Tehran, Iran). RBCs stabilized 
with EDTA were obtained from the Iranian Blood Transfusion 
Institute and used with institutional bioethics approval. A puri-
fied Milli-Q deionized water (DI) was used for all experiments 
in this study. Furthermore, all used materials for biological 
protocols, including trypsin, FBS, and Roswell Park Memorial 
Institute 1640 growth medium (RPMI) were purchased from 
Gibco BRL Life Technologies. MCF7 cells as human breast 
cancer cells were provided by Cell Bank, Pasteur Institute of 
Tehran, Tehran, Iran. This study has been conducted in full 
accordance with the World Medical Association Declaration 
of Helsinki and was done after confirmation from the eth-
ics committee of Tabriz University of Medical Sciences, 
Tabriz, Iran (as local institutional bioethics committee).
characterizations
Fourier-transform infrared (FTIR) spectroscopy was used to 
monitor the reaction process and to determine sample’s chem-
ical structure. KBr method (sample to KBr ratio is 1:50) was 
used for recording the FTIR spectra on a Bruker (Shimadzu, 
Japan). The prepared KBr disk scanned against a blank KBr 
disk at wavenumbers ranging from 500 to 4,000 cm−1. The 
nuclear magnetic resonance (NMR) spectroscopy (Bruker 
Co., Billerica, MA, USA) was performed to validate the 
chemical structure of prepared samples. D
2
O was used as a 
solvent for calixarene derivatives. The morphology, size, and 
elemental percentage analysis of samples were investigated 
using a scanning electron microscopy (SEM; FESEM-EDX; 
TESCAN 5001). Before the examination, samples were 
mounted onto a metal stub using a carbon double-sided 
adhesive tape and covered with a thin layer of gold, with 
the aid of a direct current sputter technique (Emitechk450X; 
Quorum Technologies Ltd., Lewes, UK).
Furthermore, to accurately assess the modification pro-
cess, elemental analysis was performed by using energy dis-
persive X-ray (EDX) spectroscopy. The transmission electron 
microscopy (TEM) analysis was used to show the size and 
shape of the samples (Leo 906, Zeiss, Freiburg, Germany) 
with an operating voltage of 100 kV. Before analysis, the sus-
pension was ultrasonically dispersed using a probe-type ultra-
sonic generator (400 W) for 6 seconds, and the suspension was 
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placed on a carbon-coated copper grid. Contact angle (CA) 
was used for the evaluation of hydrophilicity of the samples 
by sessile drop method. Two-microliter droplets of deion-
ized water were released slowly on the coverslips containing 
samples pressed layer. ImageJ, an image analyzer software, 
was used for measuring the droplet of water on the surface 
of the sample. For CA analysis, the powder was pressed on 
a glass slide to make a uniform and smooth thin layer. The 
magnetic properties of samples were characterized with a 
vibrating sample magnetometer (VSM) (AGFM, Kashan, 
Iran) for determination of sample’s magnetization response vs 
applied field at room temperature. The particle size distribu-
tion of samples was assessed using a dynamic laser-scattering 
technique (DLS; Zetasizer Nano ZS90; Malvern Instruments, 
Malvern, UK). Before analysis, a diluted suspension of the 
sample was prepared by PBS solution (pH 7.4) to achieve the 
required sample density for analysis.
green synthesis of magnetic nanocarrier 
based on amphoteric calixarene
synthesis of p-sulfonatocalix[4]arene (s-calix)
This compound was synthesized using a previously reported 
procedure.32 Calix (1.0 g, 2.4 mmol) was treated with concen-
trated H
2
SO
4
 (10 mL), and the mixture was stirred vigorously 
at 70°C for 3 hours. An aliquot was taken out from the solution 
and poured into water. The reaction progress was monitored 
by adding an aliquot of reaction mixture gradually into the 
deionized water. After completion of the reaction, no pre-
cipitate materials were detected in the mixture. The reaction 
mixture was allowed to cool and poured gradually into 10 mL 
deionized water. The solution was neutralized with aqueous 
Na
2
CO
3
 solution and evaporated to dryness. The residue was 
reprecipitated several times from water into absolute ethanol. 
Finally, p-sulfonatocalix[4]arene (s-Calix) was dried at 50°C 
for 24 hours, and a white crystalline solid was obtained.
synthesis of needle-shaped poly ionic liquid-grafted 
p-sulfonated calix[4]arene (PIl-calix)
Ring-opening polymerization of IL-oxirane on the surface of 
s-Calix was performed by modification of a previously reported 
method.33 s-Calix (1.0 g, 1.2 mmol) was dissolved with an 
excess amount of IL-oxirane (100 mmol) in deionized water, 
and the pH of the solution was adjusted to 1.0 by adding HCl 
solution. The mixture was stirred at 60°C under a nitrogen 
atmosphere for 24 hours. The resulting poly ionic liquid-grafted 
p-sulfonated calix[4]arene (PIL-Calix) was reprecipitated 
several times in ethanol to remove unreacted IL-oxirane. The 
obtained light brown solid (PIL-Calix) was dried in vacuum.
Preparation of PIl-calix-coated magnetic 
nanoparticles (PIl-calix/MNPs)
Briefly, PIL-Calix (1.0 g) was dissolved in 50 mL deionized 
water, and subsequently, 1.25 g of FeCl
3
⋅6H
2
O and 0.5 g of 
FeCl
2
⋅4H
2
O were added, and the solution was stirred at room 
temperature for 30 minutes to obtain a homogenous solution. 
By adding ammonia solution gradually to the above solution, 
Fe
3
O
4
 magnetic nanoparticles were formed, which modified 
with PIL-Calix at nanoparticles surface. The reaction mixture 
was stirred for 30 minutes, and the obtained PIL-Calix-coated 
magnetic nanoparticles (PIL-Calix/MNPs) were isolated by 
an external magnet and washed several times with ethanol 
and water. Finally, the formed PIL-Calix/MNP was dried in 
vacuum for further use.
Blood compatibility tests
Human whole blood was obtained from Iranian Blood Trans-
fusion Institute stabilized with EDTA and spun at 4,000 rpm 
for 10 minutes at room temperature. The plasma (upper layer) 
was discarded, and the pellets (RBCs) were isolated. The 
isolated RBCs were washed three times with PBS (pH 7.4) 
until a clear supernatant was obtained. For the blood com-
patibility of PIL-Calix/MNPs, the following three tests were 
performed according to the procedure described below.34,35
Test A – hemolysis assay: 0.5 mL suspension of PIL-
Calix/MNPs (25, 50, 100, 200, 400, and 800 µg/mL) and 
0.5 mL of diluted RBCs were mixed in a microtube and 
incubated at 37°C for 1 hour. The samples were centrifuged 
at 5,000 rpm for 5 minutes and the supernatant was trans-
ferred to the 96-well plates. ELISA plate reader was used 
to measure the released hemoglobin (at a wavelength of 
540 nm) and calculate the hemolysis percentage using the 
following formula:
 
Hemolysis rate (
Abs Abs
Abs Abs
sample PBS
water PBS
%) =
−
−
×100
 
Test B – erythrocytes aggregation test: after incubation 
of test number A, aggregation of RBCs was observed by 
phase contrast microscope (Nikon, YS2-T; Tokyo, Japan) 
with 40× magnification. Diluted RBCs treated with water 
and PBS were used as positive and negative controls with 
100% and 0% hemolytic effects, respectively.
Test C – erythrocytes sedimentation rate: 2 mL of human 
blood was drawn into the Westergren tube (a narrow vertical 
tube) containing 0.5 mL sodium citrate, 2.0 mg of PIL-Calix/
MNPs was then added, and the tube was placed in a rack in 
an upright position for 1 hour at room temperature. The rate 
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of sedimentation is measured as the number of millimeters 
of clear plasma present at the top of the column after 1 hour 
(mm/hour).
In vitro DOX and MTX loading and 
release studies
In vitro drug loading and release studies were performed 
according to the two following procedures:
Loading step: simultaneous loading of DOX and MTX 
was performed as follows: PIL-Calix/MNPs (100 mg) as a 
nanocarrier was dispersed in PBS solution (100 mg) by water 
bath sonication, and then MTX (10 mg) was added to the 
suspension and mixed moderately with a magnetic stirrer for 
24 hours. After isolation of MTX-loaded nanocarrier (MTX/
nanocarrier) and washing with PBS to remove unloaded MTX 
and DOX, loading was done as follows: MTX/nanocarrier 
was dispersed in PBS, and DOX (10 mg) was added to the 
suspension. The suspension was stirred at room temperature 
under the dark condition for 24 hours. Finally, DOX-MTX-
loaded magnetic nanocarrier (DOX-MTX/nanocarrier) was 
obtained and used in the releasing step.
Releasing step: DOX-MTX/nanocarrier (10 mg) was 
added to microtube, which was categorized as follows: 
category 1 for pH 7.4 and category 2 for pH 5.0 in triplicate. 
Two millilters of PBS solution was added to each microtube 
and incubated at 37°C. At a certain time, the microtubes were 
centrifuged, and the supernatant was taken for determination 
of released MTX and DOX by UV–Vis spectrophotometer.
cell culture
MCF7 cells as the human breast adenocarcinoma cell line 
were used in this study which was obtained from the National 
Cell Bank of Iran (Pasteur Institute of Iran, Tehran, Iran). 
The cells were cultured with RPMI 1640 medium (supple-
mented with 10% (v/v) FBS, 1% antibiotics including peni-
cillin and streptomycin with a concentration of 50 IU/mL 
and 50 µg/mL, respectively). After cell culturing, the flask 
containing cells were incubated under a fully humidified 
atmosphere at 37°C with 5% CO
2
, and growth medium must 
be renewed two to three times per week until the cells reached 
90% confluency. After sufficient PBS washing, the cells were 
detached with 0.25% trypsin in PBS (pH 7.4) and centrifuged 
at 1,500 rpm for 5 minutes.36 Subsequently, the cells were 
dispersed in growth medium and used for seeding in further 
in vitro assays.
cellular uptake
MCF7 cells were seeded in 6-well plates for quantification 
of uptake at a density of 5×104 and 5×105 cells per well 
for cellular uptake by fluorescent microscopy and flow 
cytometry assays, respectively.2 After incubation of cells for 
24 hours, the culture media of 6-well plates were replaced 
with free media. Then, the cells were treated with different 
sample suspensions including DOX-labeled nanocarrier (at 
a concentration of 10 µg/mL in PBS), and the cells with no 
treatment considered as a control. In the end, two following 
regular procedures were performed.
Cellular uptake by fluorescent microscopy: after incuba-
tion for 1, 2, and 3 hours, the cells were washed three times 
with PBS and fixed by formaldehyde (4% w/v). The coverslip 
was taken onto a glass microscope slide, and DOX/nanocarrier 
uptake was observed by using a fluorescence microscope 
(Olympus Microscope Bh2-RFCA, Tokyo, Japan).
Cellular uptake by flow cytometry: after incubation for 
1, 2, and 3 hours, the cells were trypsinized and collected 
for determination of DOX/nanocarrier uptake inside the 
cells via fluorescence intensity using a FACSCalibur flow 
cytometer (Becton Dickinson Immunocytometry Systems, 
San Jose, CA, USA).
cytotoxicity assay
The MCF7 cells at the concentration of 10×103 cells per 
well were seeded in 96-well plates and incubated under 
5% CO
2
 atmosphere for overnight at 37°C attached at the 
bottom of each well. For in vitro cytotoxicity evolutions, 
following procedure was performed. Briefly, the seeded 
cells were treated with different samples including (blank 
nanocarrier, DOX-MTX/nanocarrier, and DOX-MTX) at 
various concentrations in RPMI medium and incubated for 
48 hours. After washing several times with PBS, MTT assays 
were performed to determine the cell viability according to 
the reported procedure. The absorbance of each well was 
measured at 570 nm with an ELISA plate reader.
DaPI staining
The apoptotic effects of samples on MCF7 cells were exam-
ined by DAPI staining as a routine microscopic analysis.37 
Briefly, in 6-well plates containing sterile coverslips, 5×104 
MCF7 cells were seeded and allowed attaching at the bottom 
of each well at 37°C for overnight. The cells were treated 
with blank nanocarrier, DOX-MTX/nanocarrier, and DOX-
MTX at the concentration of IC
50
. The cells with no treatment 
were considered as a negative control. The 6-well plates were 
kept in an incubator and incubated for 48 hours. The wells 
were washed three times with PBS and fixed with 4% form-
aldehyde at ambient temperature for 15 minutes. Then cells 
were permeabilized by adding Triton X-100 (0.1% w/v) and 
incubated for 5 minutes. Ultimately, cells were stained by 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
27
 o
n 
18
-D
ec
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2623
rahimi et al
using DAPI solution (200 ng/mL), and DNA condensation 
and fragmentation in apoptotic cells were evaluated under 
a fluorescence microscope (Olympus Microscope Bh2-
RFCA, Japan).
Apoptosis assay by flow cytometry
Apoptotic effects of different formulations were measured 
by ApoFlowEx® FITC Kit (EXBIO Diagnostics, Vastec, 
Czech Republic). MCF7 cancer cells at the density of 5×105 
cells per well were seeded in 6-well plates and incubated 
for 24 hours attached at the bottom of the wells. Then, the 
cells were treated with blank nanocarrier, free DOX-MTX, 
and DOX-MTX/nanocarrier. Cells receiving only fresh 
medium were considered as control group. After incubation 
for 48 hours, cells were trypsinized, washed twice with cold 
PBS, resuspended in 1× binding buffer (500 µL), added 5 µL 
of Annexin V-FITC and 5 µL of propidium iodide, and incu-
bated for further 15 minutes in dark. Then flow cytometry 
analysis was performed by flow cytometer (FACSCalibur; 
BD Biosciences, San Jose, CA, USA).
statistical analysis
All data were reported as mean ± SD of three replicates. 
The ANOVA was used for statistical analysis. The 
P-values 0.05 were considered significant.
Results and discussion
synthesis
As shown in Figure 1A, Calix is a cavity-shaped cyclic mol-
ecule with four phenol units linked with methylene bridges 
at ortho positions. Calix has four tertiary butyl (t-butyl) 
functional groups at the para position of hydroxyl groups, 
which render them very hydrophobic. It has a crystalline 
structure under the microscope with a very light yellow 
color. After treating with concentrated sulfuric acid, the 
t-butyl groups at para position were substituted with sulfo-
nate (−SO
3
H) hydrophilic groups, and the physicochemical 
characteristics of the resulting compound were changed. The 
crystalline form of sulfonate calixarene under the micro-
scope showed the same appearance as Calix (Figure 1B). 
The sulfonate groups act as anionic active sites for loading 
Figure 1 chemical structure, appearance, and crystalline structure of calix, s-calix, and PIl-calix molecules.
Notes: calix (A), s-calix (B), PIl-calix molecules (C).
Abbreviations: calix, calix[4]arene; PIl-calix, poly ionic liquid-grafted p-sulfonated calix[4]arene; s-calix, p-sulfonatocalix[4]arene.
?? ?? ?? ?? ??????
???????? ?????? ?? ?? ? ? ????? ??? ???
?? ?? ?? ?? ? ? ??? ?? ?
???? ???????? ?????? ?? ?
? ? ?
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
27
 o
n 
18
-D
ec
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2019:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2624
rahimi et al
doxorubicin drug. On the other hand, to create cationic 
active sites on these macrocycles for loading MTX drug, 
ionic liquid polymeric chains were attached to the other 
side of macrocycles causing amphoteric Calix. The result-
ing calixarene has different appearance without crystalline 
structure (Figure 1C). All reaction processes were per-
formed in green approach with no toxic solvents, making 
the designed nanocarrier very safe for use in the biomedical 
applications (Figure 2).
characterizations
Before performing biological assays to show the safety of 
nanocarrier and its capability in combinational delivery of 
anticancer drugs in drug-delivery systems, all materials were 
characterized by several techniques including FTIR, NMR, 
differential scanning calorimetry (DSC), SEM, EDX, TEM, 
VSM, DLS, and CA. In the following section, each analysis 
was discussed as well.
All samples were characterized by FTIR and 1H NMR 
spectroscopies to determine the functional groups and chemi-
cal structure of the samples. As shown in Figure 3, the FTIR 
spectra of Calix, s-Calix, PIL-Calix, and PIL-Calix/MNPs 
were taken. The FTIR characteristic absorbance and 1H NMR 
chemical shifts of the samples are given below.
Calix: the characteristic absorption peaks at 670, 
1,242, 1,481, 2,956, 3,049, and 3,201 cm−1 are attributed to 
Figure 3 FTIr spectra of calix (A), s-calix (B), PIl-calix (C), and PIl-calix/MNPs 
(D) at wavenumber range of 500–4,000 cm−1.
Abbreviations: calix, calix[4]arene; PIl-calix, poly ionic liquid-grafted p-sulfonated 
calix[4]arene; PIl-calix/MNPs, PIl-calix-coated magnetic nanoparticles; s-calix, 
p-sulfonatocalix[4]arene.
Figure 2 (A) Preparation of p-sulfonatocalix[4]arene (s-calix) from 4-tert-butylcalix[4]arene (calix). (B) Preparation of needle-shaped poly ionic liquid-grafted p-sulfonated 
calix[4]arene (PIl-calix) via ring-opening polymerization of Il oxirane (step 1) and preparation of PIl-calix-coated magnetic nanoparticles (PIl-calix/MNPs) as a magnetic 
nanocarrier (step 2).
?? ?????????
?????????????? ????? ??
????
? ? ???? ?? ??????? ?????
?
???????????????? ???????????????????????????????????
????????????????????????????????????????
????????
???????????? ???????°???????????????????????? ?? ?? ?? ?????? ???? ???? ?????? ?? ?? ?? ?? ????
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the =C-hour bending, C−O stretching, C=C stretching, ali-
phatic C−H stretching, aromatic C−H stretching, and O−H 
stretching bonds, respectively. Due to the presence of the 
t-butyl group substituted at the para position of phenol, the 
intensity of the peaks at around 2,956 is high.
1H-NMR (400 MHz, CDCl
3
, δ ppm): 10.3 (OH, s, 4 H), 
7.05 (Ar-H, s, 8 H), 4.25 (CH
2
, d, 4 H), 3.49 (CH
2
, d, 4 H), 
and 1.21 (t-Bu, s, 36 H).
s-Calix: the characteristic peaks at 669, 1,045, 1,186, 
1,213, 1,471, 2,954, 3,190, and 3,446 cm−1 are assigned to 
the =C-H bending, asymmetric stretching vibration of S−O, 
C−O stretching, splitting of the S=O group into symmetric 
and asymmetric stretching vibrations, C=C stretching, ali-
phatic C–H stretching, aromatic C−H stretching, and O−H 
stretching bonds, respectively.
1H-NMR (400 MHz, D
2
O, δ ppm): 7.60 (ArH, s, 8 H) 
and 3.84 (CH
2
, S, 8 H).
PIL-Calix: as the PIL-Calix has polymeric chains on its 
structure with several methylene groups (−CH
2
−), −C−N=, 
−C=N−, and −C−OH, it was expected that some new peaks 
or shifting absorption peaks were observed. Regarding the 
formation of many methylene groups in the polymeric chains, 
the absorption peaks at 2,961 cm−1 were enhanced in compari-
son to the s-Calix. The characteristic peak of −C=N− sections 
was appeared at 1,680 cm−1, whereas the peak of −C−N= was 
not appeared clearly because of its low intensity. Identical 
peaks in both s-Calix and PIL-Calix appeared at the same 
range of wave number with slight shifting.
1H-NMR (400 MHz, D
2
O, δ ppm): 8.58 (N=CH, s), 7.60 
(ArH, s, 8 H), 7.32–6.94 (NCH, m), 4.18 (NCH3, s), 3.84 
(CH2, S, 8 H), and 3.5–3.22 (OCH2CHCH2N, m).
PIL-Calix/MNPs: after surface modification of magnetic 
nanoparticles (Fe
3
O
4
) with PIL-Calix, the characteristic peaks 
of both Fe
3
O
4
 and PIL-Calix were observed. Fe
3
O
4
 has a bulk 
network with two clear peaks at 573 and 3,458 cm−1 for Fe−O 
and O−H. By following the PIL-Calix/MNPs spectrum, the 
characteristic peaks of PIL-Calix were also found with low 
intensity. All observations and results validated our prepara-
tion process.
DSC is a technique for analyzing the thermal behavior 
of the sample according to the amount of heat required to 
increase the temperature. The DSC graph is depicted based 
on heat flow vs temperature. The DSC thermographs of 
Calix, s-Calix, and PIL-Calix are shown in Figure 4. Calix 
showed a uniform curve with no exothermic and endothermic 
peaks in the analysis temperature range, and it has no phase 
transition with a melting point above this range (melting 
point 300°C). However, s-Calix has a sharp exothermic 
peak in the temperature range of 50°C–100°C, which is 
attributed to the recrystallization of molecules with high 
heat releasing rate. At this point, the fragments may obtain 
enough freedom of motion to arrange themselves into a 
crystalline form spontaneously. Due to the presence of 
polymeric branches on the PIL-Calix, it was expected that 
the recrystallization temperature shifted to the higher tem-
perature because the polymeric chains prevent rearrangement 
of the molecules in lower temperature. By observing the 
DSC graph of PIL-Calix, the height of the curve was more 
depressed than unmodified s-Calix and can be concluded that 
low exothermic heat was released. All results confirmed that 
the modification in each step was successful.
The water CA is a measure of the wettability of the solid 
surface. If the solid surface is highly hydrophilic, water 
droplet is strongly attracted, and then the water drop will 
completely spread out with CA (θ) of 0°. In general, water CA 
lower and more substantial than 90° is considered hydrophilic 
and hydrophobic solid surfaces, respectively. Regarding 
this, an appropriate amount of each sample was placed on a 
glass slide, and another glass slide was fixed on the sample. 
The glass slides were placed in the pressure instrument, and 
the sample was pressed slowly. The obtained disk on glass 
slide had a homogenous surface. Given that the conditions are 
the same, the results could be compared to each other. Since 
Calix contains four t-butyl groups, which cause it highly 
hydrophobic, its water CA value could not be measured by 
instrument due to the high hydrophobicity and escaping from 
the water. Figure 5 showed that the droplet could not separate 
and stand on the surface. (This picture was snapshotted from 
the video of the measurement process.) After exchanging 
?? ? ? ????????? ?? ??? ????????????????°???????????????
???????????
??? ???
Figure 4 Dsc thermographs of calix (A), s-calix (B), and PIl-calix (C) from 30°c 
to 250°c at a heating rate of 5°C/min under a flowing nitrogen atmosphere.
Abbreviations: calix, calix[4]arene; Dsc, differential scanning calorimetry; 
PIl-calix, poly ionic liquid-grafted p-sulfonated calix[4]arene; s-calix, 
p-sulfonatocalix[4]arene.
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the t-butyl groups with sulfonate (−SO
3
H) group to yield 
s-Calix, it was expected that the hydrophilicity enhanced 
after substitution of t-butyl with sulfonate and the amount 
of θ decrease to lower degree (34.01). The hydrophilicity 
of PIL-Calix was also evaluated and results showed that 
water droplet could spread out easily on the surface of film 
with θ value of 28.83. All samples were tested in triplicate 
at three different areas, and obtained midpoint results were 
reported. Overall, the results data confirmed that the present 
modification process was done.
The surface morphology of Calix, s-Calix, PIL-Calix, and 
PIL-Calix/MNPs was studied by SEM analysis and illustrated 
in Figure 6. Calix has a solid structure with finger-like beads 
and smooth surface. The s-Calix also has finger-like beads. 
However, its morphology was changed to rough form with 
several fractions on it. Further evaluation revealed that each 
bead was changed to multilayer structure. Surface morphol-
ogy of PIL-Calix revealed that the structure of s-Calix was 
?
? ?
θ?????????????????????
ϕ?????????????????????? θ?????????????????????ϕ??????????????????????
Figure 5 Water drop contact angle for hydrophobic calix (A) and hydrophilic 
s-calix (B), and PIl-calix (C) samples.
Abbreviations: calix, calix[4]arene; PIl-calix, poly ionic liquid-grafted p-sulfonated 
calix[4]arene; s-calix, p-sulfonatocalix[4]arene.?
???? ????????????? ???????? ????????????????????????????? ??????????????????? ???????????
?
???? ????????????? ???????? ????????????????????????????? ??????????????????? ????????????
???? ????????????? ???????? ????????????????????????????? ??????????????????? ???????????
?
?????? ????????????? ???????? ????????????????????????????? ??????????????????? ???????????
Figure 6 surface morphology and size of calix (A), s-calix (B), PIl-calix (C), and PIl-calix/MNPs (D) by seM technique at the scale of 1 µm, 1 µm, 1 µm, and 300 nm, 
respectively.
Abbreviations: calix, calix[4]arene; PIl-calix, poly ionic liquid-grafted p-sulfonated calix[4]arene; PIl-calix/MNPs, PIl-calix-coated magnetic nanoparticles; s-calix, 
p-sulfonatocalix[4]arene; seM, scanning electron microscopy.
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completely altered to various and specific shapes, which 
will facilitate the attachment of drug molecules onto the 
surface and PIL-Calix cavities. After surface modification 
of magnetic nanoparticle with PIL-Calix, spherical particles 
with nanosize around 40–50 nm were formed. The SEM 
image demonstrated that prepared PIL-Calix/MNPs tended 
to aggregate in aqueous solution because of the small size 
effect caused by hydrophilic units of the compound on the 
Fe
3
O
4
 nanoparticles. All observations confirmed that surface 
modification processes were performed successfully.
EDX spectroscopy (EDS) or EDX is an analytical tech-
nique for chemical characterization and determination of the 
elemental analysis. EDS can be used to estimate chemical 
elements relative abundance. Several factors (such as over-
lapping X-ray emission peaks, the nature of the sample, etc) 
affected the accuracy of the sample compositions. Fe
3
O
4
 
NPs were synthesized and used as a control. As seen in 
the EDS spectrum (Figure 7), the atomic percentage of the 
iron atom (Fe) is 40.17%±6.65% with two characteristic 
peaks at 0.705 and 6.398 keV. Also, the oxygen atom (O) 
has 59.83%±5.98% atomic percentage with a characteristic 
peak at 0.525 keV. After preparation of PIL-Calix/MNPs 
by in situ synthesis of Fe
3
O
4
 NPs in PIL-Calix solution, 
the EDS analysis was taken, and the atomic percentages 
were reported. As seen in the spectrum, two new peaks 
of carbon (C) and nitrogen (N) were appeared at around 
0.277 and 0.392 keV, respectively, with atomic percentage 
of 22.28%±6.23% and 3.64%±0.87%. As X-ray emission 
peaks of N and O elements appears close to each other, 
their peaks were overlapped with each other. By appearance 
of these elements, the intensity of Fe and O elements was 
decreased. All results validated the successful preparation 
of PIL-Calix/MNPs. The elemental analysis data were sum-
marized in Table 1.
To receive more direct information on the particle size 
and morphology, TEM micrographs of PIL-Calix/MNPs 
were investigated. As shown in Figure 8, TEM image shows 
a difference in morphology. Some needle- and rod-shaped 
calixarene-doped magnetic nanoparticles were also observed, 
where magnetic nanoparticles formed on the surface of PIL-
Calix needles and rods. Many dense aggregations of pure Fe
3
O
4
 
magnetic nanoparticles were observed, due to the lack of repul-
sive force. After PIL-Calix immobilization, the dispersion of 
particles was improved as well, which can easily be explained 
by the electrostatic repulsion force and steric hindrance between 
the Calix and the surface of Fe
3
O
4
 nanoparticles.
To measure magnetic properties of magnetic materi-
als, VSM was used, and the magnetization value (emu/g) 
vs applied field (Oe) was determined at room temperature 
????
??????
?
??
??
??? ????? ???????
????????
??????? ?
???? ?? ??? ? ?????
? ?
Figure 7 The eDs spectra of Fe3O4 (A) and PIl-calix/MNPs (B) for the estimation of the elemental analysis.
Abbreviations: eDs, energy dispersive X-ray spectroscopy; PIl-calix/MNPs, PIl-calix-coated magnetic nanoparticles.
Table 1 elemental analysis data based on weight percentage 
(W%) and atomic percentage (a%)
Element Fe3O4 PIL-Calix/MNPs
Fe 70.09±8.26 40.17±6.65 23.79±3.21 7.71±1.29
O 29.91±5.22 59.83±5.98 58.62±9.01 66.36±9.74
c – – 14.77±2.09 22.28±6.23
N – – 2.80±0.88 3.64±0.87
Total 100.00 100.00 100.00 100.00
Abbreviation: PIl-calix/MNPs, PIl-calix-coated magnetic nanoparticles.
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(Figure 9). The prepared nanocarrier displayed saturation 
magnetization equal to about 62 emu/g, which has lower 
amount than Fe
3
O
4
 NPs as a control (with magnetization 
value of 74 emu/g), and it is attributed to the presence of a 
polymeric branch of PIL-Calix on the magnetic core. The 
S shape of the magnetic nanocarrier diagram exhibited zero 
coercivity and permanence, thus indicating its superpara-
magnetic feature. Therefore, this property of nanocarrier 
could carry chemotherapeutic agents to the target cells by 
using a permanent external magnet. After using an external 
magnet, the separation time for collecting magnetic nano-
carrier beside the container is about 20 seconds. All results 
confirmed that the nanocarrier is suitable for use in the 
pharmaceutical field.
Despite the size of the magnetic nanoparticles was 
observed and calculated by SEM analysis. Particle size 
can be determined by measuring the random changes in 
the intensity of light scattered from a suspension. DLS is a 
proper technique that is most commonly used for analyz-
ing nanoparticle size distribution. However, this technique 
was performed in an aqueous solution to enable particles 
to interact with each other freely, which caused aggrega-
tion. As seen from the DLS graph of prepared nanocarrier 
(Figure 10), the size distribution is around 210 nm.
stability of nanocarrier in the 
physiological condition
The colloidal behavior of PIL-Calix/MNPs as a magnetic 
nanocarrier was investigated, and the results discussed as 
follows. The colloidal stability of magnetic nanoparticles 
(Fe
3
O
4
 NPs) in an aqueous solution depends on the environ-
mental parameters and their intrinsic magnetic properties. 
However, the surface modification of nanoparticles could 
enhance its stability, bioavailability, and toxicity. Several 
parameters (such as pH, ionic strength, and plasma protein 
concentration) were affected by the properties of magnetic 
nanoparticles in physiological condition. Therefore, we used 
a common culture medium (RPMI 1640), which contained 
mono and divalent ions (Na+, Mg2+, and Ca2+), and FBS was 
also added to the culture medium for cell culturing and it 
provided the simulated condition of the physiological body. 
As the stability could be affected by altering nanoparticles 
concentration, two different concentrations with the low and 
high amount of magnetic nanocarriers (0.1% and 1%) were 
evaluated. The results showed that magnetic nanocarrier sta-
bility in both concentrations has not changed after incubation 
in culture medium for 10 days and no significant macroscopic 
changes were observed. This demonstrates that the stability 
of magnetic nanocarrier in physiological conditions is a 
complex function of nanoparticles surface characteristics 
and components of the surrounding medium. The results 
confirmed that the suspension has good stability with low 
rate sedimentation, which breaks down the aggregation by 
sonication or stirring. To show the diffusing capability of 
nanocarrier, a droplet of nanocarrier suspension was added to 
the simulated physiological condition medium with PBS, and 
??????????????????????????????????????????
?????????
?????
Figure 8 TeM micrograph of PIl-calix/MNPs with a needle-shaped structure.
Abbreviations: PIl-calix/MNPs, PIl-calix-coated magnetic nanoparticles; TeM, 
transmission electron microscopy.
???????????????????
???????
??
????????????????????????????????
?????????????
? ????? ??????
Figure 9 VsM analysis was applied to measure the magnetic properties of prepared 
nanocarrier at room temperature.
Abbreviation: VsM, vibrating sample magnetometer.
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a series of pictures were snapshotted. As shown in Figure 11, 
the nanocarrier could easily disperse in the container.
Drugs loading and release studies
High loading drugs on the drug carrier for increasing 
therapeutic efficiency is an important role in the field of 
nanoparticulate drug-delivery systems. Regarding this issue, 
high-capacity drug-delivery system for loading combination 
anticancer drugs was designed based on amphoteric Calix. 
DOX and MTX were used as the model drugs with two dif-
ferent moieties (amine and carboxylic acid functional groups, 
respectively). Measurement of two important parameters 
is essential in drug-delivery systems including loading 
and encapsulation efficiencies; their calculation formula 
is shown below. After calculation of both parameters for 
both DOX and MTX, the obtained values of loading and 
encapsulation efficiencies for DOX were 9.02%±2.47% 
and 90.22%±5.08%, respectively. However, the values 
of these parameters for MTX were 5.86%±1.79% and 
58.62%±6.53%, respectively. These values are related to the 
presence of cationic and anionic functional groups on drugs 
and drug carrier at the loading condition (PBS pH 7.4). The 
interactions are hydrogen bonding and electrostatic interac-
tion. It is assumed that the drugs could release by changing 
the medium condition and causing repulsion between drugs 
and drug carrier. In this regard, drug release profile was simu-
lated in both physiological and cancerous tissue conditions. 
DOX-MTX/nanocarrier was dispersed in PBS solution in 
both pH 7.4 and 5.0, and release profiles were evaluated for 
1 week (168 hours) (Figure 12). Both DOX and MTX release 
profiles have burst release in first and then sustain release 
after 1 day. The burst release of both drugs is attributed to the 
physical interaction between drug-carrier and drugs, so the 
drugs could easily separate from nanocarrier surface. After 
release study for 168 hours, DOX and MTX showed about 
83.26% and 87.93% of cumulative releases, respectively.
Biocompatibility of nanocarrier
In biomedical applications, nanomaterials enter the body 
and contact with tissues and cells directly. It is essential 
to analyze their biocompatibility. RBCs, also called 
erythrocytes, represent the most abundant cellular con-
stituent of the blood (99%), which plays an essential 
role in human health. Nanomaterials in drug-delivery 
systems are directly contacted with RBCs. Thus they 
are examined for their blood-compatible behaviors.38 
Several experiments including hemolysis assay, coagula-
tion, erythrocytes aggregations, and sedimentation rate 
have been carried for evaluation of biocompatibility of 
biomaterials before using in biomedical applications.34 
In this study, hemolysis assay and erythrocytes sedimen-
tation rate experiments as reliable and straightforward 
measures were chosen for estimating blood compatibility 
??????
??????
??
? ?? ????????????
???????
??? ????? ??????
Figure 10 Particle size distribution of prepared nanocarrier by Dls technique at physiological condition (ph 7.4 and 37°c).
Abbreviation: Dls, dynamic laser scattering.
? ? ? ?
Figure 11 Diffusing capability of nanocarrier in simulated physiological condition 
after intravenous injection (ph 7.4 and 37°c).
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??????
???????
?? ?? ?? ????? ????????????????
???????
??? ??? ??? ??????
???????
?? ?? ?? ????? ????????????????
???????
??? ??? ???
???????????? ????????????
Figure 12 The cumulative release of MTX and DOX from DOX-MTX/nanocarrier at two ph values (5.0 and 7.4) at 37°c.
Abbreviation: DOX-MTX/nanocarrier, DOX-MTX-loaded magnetic nanocarrier.
of materials. By treating RBCs (erythrocytes) with various 
concentrations of nanocarrier (25, 50, 100, 200, 400, and 
800 µg/mL), hemolytic effects were calculated using the 
hemolysis rate formula. As hemolysis rate has a direct 
relationship with the concentration of nanocarrier, a 
negligible hemolytic effects on RBCs was observed with 
2.77% hemolysis percentage even at high treated dosage. 
The results of the aggregation test on RBCs showed that 
nanocarrier has no effect on RBCs membrane charge 
and no aggregation occurred (Figure 13B). To evaluate 
the impact of nanocarrier on RBCs membrane charge, 
erythrocyte sedimentation rate (ESR) was calculated. 
The ESR is the rate of RBCs sedimentation in 1 hour 
(the ESR test is a nonspecific measure of inflammation 
??? ??????? ? ??????
????? ??? ?? ?? ??? ??? ??? ????? ????????????????????
?????????
?? ??? ?? ?? ??? ????????????????????? ????? ??? ?????
? ?
Figure 13 Three common blood compatibility analysis for determination of sample safety in blood-contacting biomedical applications. hemolysis assay (A), rBcs aggregation 
test (B), and erythrocytes sedimentation rate analysis (C).
Abbreviations: PBs, phosphate buffered saline; rBcs, red blood cells.
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and hematology test). After treating RBCs with nanocar-
rier at the dosage of 1,000 µg/mL in a Westergren tube 
(upright tube) (containing citrate as an anticoagulant 
agent), the amount of sedimentation in both treated and 
untreated RBCs has no significant changes after 1 hour 
(Figure 13C). To make sure that our nanocarrier has no 
bad effects on the RBCs surface charge, more incubation 
time for interacting RBCs with nanocarrier was also done 
and results showed no significant difference. Ultimately, 
based on the results of three common blood experiments, 
it was expected that the developed nanocarrier is safe for 
using in blood-contacting biomedical applications.
cellular internalization
The interactions of nanoparticles with the soft surfaces of 
biological systems such as cells play vital roles in execut-
ing their biomedical functions and in toxicity. Cells have a 
permeable membrane through which small molecules could 
easily enter into them by several pathways (concentration 
gradients, active transport system such as protein pumps and 
ion channels, and endocytosis).39 Endocytosis is a pathway 
that internalizes nanomaterials in transport vesicles derived 
from the plasma membrane.40 As our magnetic nanocarrier 
has a size of 100 nm, it could be internalized into the cells 
by energy-dependent clathrin-mediated endocytosis in which 
nanocarrier is deposited in small endocytic vesicles and 
fuse with early endosomes.41 To understand the nanocarrier 
capability in the cellular uptake process, cellular uptake was 
performed by fluorescent microscopy and flow cytometry 
analysis (two complementary methods). First, the MCF7 
cells were treated with DOX-labeled nanocarrier in a time-
dependent manner (1, 2, and 3 hours). As shown Figure 14, 
all cells could uptake the DOX-labeled nanocarrier showing 
fluorescent light. In the next step, flow cytometry analysis was 
used to measure the uptake percentage and amount of fluo-
rescent intensity (Figure 15). The results were confirmed by 
fluorescent microscopy observations and also showed that by 
increasing treating time, fluorescent intensity was enhanced. 
Ultimately, it could be concluded that our nanocarrier has 
good internalization capability into the cells, which is a cru-
cial role for the delivery of anticancer agents into the cells.
cytotoxic assay by MTT assay
For assessing cell metabolic activity and cytotoxicity effects 
of samples DOX-MTX, DOX-MTX/nanocarrier, and blank 
nanocarrier on MCF7 breast cancer cells, the MTT assay 
was performed for 48 hours (Figure 16). Before comparing 
the cytotoxic effects of anticancer drugs in free and nanofor-
mulation form, the MCF7 cells (considered as model cells) 
were treated with blank nanocarrier to be sure for nanocar-
rier biocompatibility. The results revealed that nanocarrier 
has low cytotoxic effects on cells in the concentration range 
of 2–128 µg/mL equivalent to 99.76%–92.71% cell viability 
in a dose-dependent manner. By increasing the nanocar-
rier concentration, the cell viability was decreased, which 
attributed to the sedimentation of nanocarrier on attached 
????? ????? ?????
????? ????? ?????
? ? ?
Figure 14 cellular uptake of DOX-labeled nanocarrier by McF7 cells after treatment for 1 (A), 2 (B), and 3 hours (C) by fluorescent microscopy.
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cells in the wells and causing hypoxia (deficiency in the 
amount of oxygen reaching the tissues). The cytotoxic 
effects of DOX and MTX on MCF7 cells were evaluated, 
and their inhibition concentration (IC
50
) was measured and 
reported (the IC
50
 of both drugs are 7.22 and 9.52 µg/mL, 
respectively). The cell treated with DOX-MTX/ nanocarrier 
has low viability in comparison to DOX-MTX, and it could 
be related to the capability of nanocarrier internalization 
into the cells and releasing the drugs with control man-
ner. Free drugs can be quickly pumped out by drug efflux 
transporters, which cause limitations for successful cancer 
chemotherapy (Figure 17). However, using drugs in nano-
formulation form overcomes the transporter-mediated 
multidrug resistance due to the passing through of nano-
carrier from the cellular membrane and releasing drugs in 
a controlled manner.
?????? ?? ????? ??????? ? ? ????????? ??? ??? ??? ?????????
???
Figure 15 Cellular uptake percentage by flow cytometry after treatment for 1 (A), 2 (B), and 3 hours (C).
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Figure 16 MTT assay for evaluation of cytotoxic effects of DOX-MTX, DOX-MTX/nanocarrier and blank nanocarrier on McF7 breast cancer cells for 48 hours.
Abbreviation: DOX-MTX/nanocarrier, DOX-MTX-loaded magnetic nanocarrier.
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Based on ANOVA test results, there are significant dif-
ferences between and within groups (DOX-MTX/nanocarrier 
and free DOX-MTX groups) with a P-value 0.001. The post 
hoc Tukey’s analysis was also performed and results showed 
that there are significant differences with P-value 0.001, 
except some dosages that showed P-value 0.05 (1 with 7), 
(3 and 8), (4 and 9), (5 and 10), and (6 and 11) (Table 2).
apoptotic effect evaluation by DaPI 
staining and flow cytometry
DAPI is a common nuclear and chromosome counterstain, 
which emits blue fluorescence upon binding to AT regions of 
DNA. According to the DAPI characteristic, the nucleus of 
MCF7 cells treated with blank nanocarrier, DOX-MTX, and 
DOX-MTX/nanocarrier was stained with DAPI and observed 
under fluorescent microscopy. To compare the nuclear 
morphological changes of cells, the cells with no treatment 
considered as a control. The normal nucleus of cells has a 
size within a defined range, while changes in nuclear size 
and shape are associated with a variety of reasons. As shown 
in Figure 18A and B, the cells of control and treated groups 
with blank nanocarrier have an entire nuclear structure with 
normal morphology and different size of the nucleus. After 
treating cells with blank nanocarrier, the population of cells is 
Table 2 MTT test results of McF7 cells treated with DOX-MTX/nanocarrier with P-value 0.001
DOX-MTX group DOX-MTX/nanocarrier group
No Drug treating  
dose
Cell  
viability ± SD
No Drug treating 
dose
Cell  
viability ± SD
1 0.312 69.270±1.549 7 0.312 68.936±2.679
2 0.625 60.299±1.016 8 0.625 51.299±2.227
3 1.250 50.779±1.762 9 1.250 46.779±3.609
4 2.500 41.609±1.537 10 2.500 32.609±2.620
5 5.000 27.733±2.758 11 5.000 20.399±2.208
6 10.000 21.606±1.113 12 10.000 12.458±2.115
Abbreviation: DOX-MTX/nanocarrier, DOX-MTX-loaded magnetic nanocarrier.
???????
???????????????????
???????????????????????????????????????????????????????
?????????
?????????
?????????
????????????????????????????????????????????????
Figure 17 Drug-loaded nanocarrier internalization into the cells and releasing the drugs with control manner (Pathway A). Easily pumping out of free drugs by drug efflux 
transporters with low cytotoxic effects (Pathway B).
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Figure 18 Fluorescent microscopic images of DaPI-stained cells following 48-hour treatment with fresh culture medium as a control (A), blank nanocarrier (B), free DOX-
MTX (C), and DOX-MTX/nanocarrier (D).
Abbreviation: DOX-MTX/nanocarrier, DOX-MTX-loaded magnetic nanocarrier.
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Figure 19 The apoptotic effects of MCF7 cells, determined by flow cytometry, for untreated cells as a control (A), blank nanocarrier (B), free DOX-MTX (C), and DOX-
MTX/nanocarrier (D).
Abbreviation: DOX-MTX/nanocarrier, DOX-MTX-loaded magnetic nanocarrier.
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the same as control. Whereas the cells treated with free drugs 
and drug-loaded nanocarrier have shown significant morpho-
logical changes with nuclear fragmentation, condensation, and 
nucleolus pyknosis (Figure 18C and D). The results showed 
that the formulated drug with nanocarrier has the apoptotic 
effects on the treated cells such as the chemotherapeutic agents.
The MCF7 cells were stained with annexin V and PI 
for apoptosis analysis after treatment with free DOX-MTX, 
DOX-MTX/nanocarrier, and blank nanocarrier for 48 
hours. The cells with no treatment were considered as the 
control group. Based on the flow cytometric analysis, blank 
nanocarrier causes death of some cells because of hypoxia 
effects of sedimentation nanocarriers on the cells, and results 
suggest that the nanocarrier is safe to use in drug-delivery 
systems. Furthermore, the apoptotic effects of the DOX-
MTX/nanocarrier and free DOX-MTX were examined with 
a higher apoptosis rate for the drug-loaded nanocarrier in 
comparison to the free drugs. As shown in Figure 19, the 
apoptosis percentage of treated cells was reported.
Conclusion
A needle-shaped Calix with amphoteric feature was synthe-
sized by a green method for codelivery of DOX and MTX to 
the MCF7 cancer cells. The developed nanocarrier has high 
stability with compatibility to the RBCs and human body 
condition. Both drugs were loaded on the nanocarrier, and the 
biological assays were performed to show its ability in a bio-
medical application such as drug-delivery systems. Three blood 
compatibility tests were examined, and results showed that 
designed nanocarrier has low hemolytic effects, erythrocytes 
sedimentation, and aggregation. Cellular uptake by fluorescent 
microscopy and flow cytometry analysis showed that nanocar-
rier could internalize into the cells easily in the first treatment.
Regarding the high internalization of nanocarrier into the 
cells, the cytotoxicity assay was performed, and the results 
showed that drug-loaded nanocarrier has good efficacy in 
killing cells, and this is related to the drugs releasing with 
control and sustained manner. Other assays such as DAPI 
staining and annexin V and PI were performed to show the 
apoptotic effect of drug-loaded nanocarrier in comparison 
to the free drugs. As a result, the developed nanocarrier is a 
promising effective vehicle for the codelivery of therapeutic 
agents and has excellent capability to deliver other biological 
agents such as genes and antibiotics.
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